Pavion Blue Capital LLC Purchases Shares of 2,345 Gilead Sciences, Inc. (NASDAQ:GILD)

Pavion Blue Capital LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,345 shares of the biopharmaceutical company's stock, valued at approximately $217,000.

Several other large investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Finally, Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $31,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 713,000 shares of company stock valued at $67,945,181 over the last quarter. Insiders own 0.16% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $109.95 on Friday. The firm has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The firm's fifty day moving average is $95.41 and its 200-day moving average is $88.73. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $111.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is currently 832.43%.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Morgan Stanley raised their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a report on Monday, November 18th. Finally, Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.